Matthew Lei
Harvard University
21 Papers
16 Citations
Matthew Lei is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 4, co-authored 10 publications. Previous affiliations of Matthew Lei include Henry Ford Hospital.
Chat about Author
Papers
The Incidence, Risk Factors, and Outcomes With 5-Fluorouracil-Associated Coronary Vasospasm.
Amna Zafar,Zsofia D. Drobni,Ramya C. Mosarla,Raza M. Alvi,Matthew Lei,Uvette Lou,Vineet K. Raghu,Sean P. Murphy,Maeve Jones-O'Connor,Sarah Hartmann,Hannah K Gilman,Colin D. Weekes,John W. Clark,Jeffrey W. Clark,Lawrence S. Blaszkowsky,Erica Tavares,Tomas G. Neilan +16 more
- 01 Mar 2021
TL;DR: In this paper, the authors conducted a retrospective analysis of all patients who received 5-fluorouracil (5-FU) at a single tertiary care center from January 2009 to July 2019.
46
Current Treatment Strategies for Multiple Myeloma.
Andrew R. Branagan,Matthew Lei,Uvette Lou,Noopur Raje +3 more
- 10 Jan 2020
TL;DR: The strategy of triplet therapies for patients with newly diagnosed MM, followed by high-dose chemotherapy and autologous stem-cell transplantation for eligible patients, and subsequently consolidation and maintenance therapy, is the current treatment roadmap for patients.
41
Current management and emerging treatment strategies for multiple myeloma.
TL;DR: Current management of transplant eligible and ineligible newly diagnosed patients in both the upfront and relapsed refractory setting is summarized, highlighting risk adapted strategies.
14
The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm
Amna Zafar,Zsofia D. Drobni,Matthew Lei,Carlos Gongora,Thiago Quinaglia,Uvette Lou,Ramya C. Mosarla,Sean P. Murphy,Maeve Jones-O'Connor,Ali Mahmood,Sarah Hartmann,Hannah K Gilman,Colin D. Weekes,Ryan D. Nipp,John W. Clark,Jeffrey W. Clark,Lawrence S. Blaszkowsky,Erica Tavares,Tomas G. Neilan +18 more
TL;DR: Re-challenge after pre- treatment with CCBs and nitrates guided by a cardio-oncology service was safe and allowed continued 5-FU therapy and there was no difference in efficacy or the recurrence of vasospasm among patients who received pre-treatment with a single agent or combination therapy.
Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma.
Jacob D. Soumerai,Allison C. Rosenthal,Shannon K. Harkins,Jessica Duffy,Carmen Mecca,Yingying Wang,Ravinder K. Grewal,Areej El-Jawahri,Huiyun Liu,Cédric Ménard,Ahmet Dogan,Lei Yang,Lisa M. Rimsza,Kurt S. Bantilan,Haley Martin,Matthew Lei,Sydney Mohr,A. Kurilovich,O. Yu. Kudryashova,E A Postovalova,Valentina Nardi,Jeremy S. Abramson,Roberto Chiarle,Andrew D. Zelenetz,Abner Louissaint +24 more
TL;DR: The generation of the first ALK-positive large B-cell lymphoma patient-derived xenograft model is reported, in which it is shown that next-generation ALK inhibitors are therapeutically active, and data support use of alectinib and lorlatinib as off-label therapeutic options for patients with relapsed or refractory ALK.